Article
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Clinical lymphoma, myeloma & leukemia - 1 Feb 2026
Chien Kelly S, Loghavi Sanam, Sasaki Koji, McCue Deborah, Daver Naval G, Kadia Tapan M, Ravandi Farhad, Short Nicholas J, Issa Ghayas C, Montalban-Bravo Guillermo, Haddad Fadi G, Hammond Danielle E, Swaminathan Mahesh, Bazinet Alexandre, Bataller Alex, Bouligny Ian, Pierce Sherry A, Garcia-Manero Guillermo, Kantarjian Hagop M, DiNardo Courtney D
Abstract excerpt
BACKGROUND: IDH1 mutations correlate with poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), though this has evolved with targeted therapy. Olutasidenib, a selective oral IDH1 inhibitor, was approved for relapsed/refractory (R/R) AML in 2022. METHODS: We investigated a single-institution experience with olutasidenib regimens in IDH1-mutated AML and MDS. RESULTS: The study included...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.